It may produce analgesic, anti-inflammatory and antipyretic effects mainly by inhibiting the synthesis of prostaglandins

It may mainly produce antipyretic and analgesic effects by inhibiting the synthesis of prostaglandins. Its analgesic effect is weak, it has no obvious anti-inflammatory effect, and has no obvious effect on platelet function.

It has a broad-spectrum antibacterial effect, and its activity against almost all bacterial species is 2 to 4 times stronger than that of norfloxacin and enoxacin, and is equivalent to that ofloxacin, and its mechanism of action is the same as that of norfloxacin. Its antibacterial spectrum is similar to that of norfloxacin, and its minimum inhibitory concentration (MIC90) against Enterobacter, Pseudomonas aeruginosa, Haemophilus influenzae, Neisseria gonorrhoeae, Streptococcus, Legionella, Staphylococcus aureus, Bacteroides fragilis, etc. is 0.008 to 2 mu;g/ml, which is significantly better than other similar drugs and antibiotics such as cephalosporins and aminoglycosides, and is often effective against pathogens resistant to beta-lactams or gentamicin.

This product is a non-steroidal anti-inflammatory drug. It has anti-inflammatory, antipyretic and analgesic effects. Its mechanism of action may be to inhibit the synthesis of prostaglandins (PG) by blocking the activity of cyclooxygenase.

Peramivir is a cyclopentane anti-influenza virus drug that can bind to the active site of influenza virus neuraminidase and has inhibitory activity against human influenza A and B viruses. Biochemical analysis showed that peramivir could inhibit the neuraminidase activity of several influenza A and B virus strains, with a median ICso value of 0.2nM (0.09~1.4nM, n=15) for influenza A virus strains, a median ICco value of 1.3nM (0.06~11nM, n=8) for influenza B virus strains, and an ICso value range of 0.06~0.26nM for 2009 HINIA influenza virus strains (swine flu). The antiviral activity of peramivir against laboratory virus strains and clinically isolated virus strains was investigated in cell culture experiments. The ECs0 value for seasonal influenza A HIN1 strain is 1μM (0.09~21μM, n=5), the ECso value for influenza A H3N2 strain is 0.07μM (0.01~0.16μM, n=12), and the ECso value for influenza B strain is 2.2μM (0.06~3.2uM, n=5). Limited biochemical analysis, cell culture and animal model data show that the antiviral activity of peramivir and oseltamivir is synergistic.

This product is a second-generation cephalosporin antibiotic. After oral absorption through the gastrointestinal tract, it is rapidly hydrolyzed into cefuroxime under the action of esterase to exert its antibacterial effect. The activity against Gram-positive cocci is similar to or slightly worse than that of the first-generation cephalosporins, but it is quite stable against beta-lactamase produced by Staphylococci and Gram-negative bacilli. Except for methicillin-resistant Staphylococci, Enterococci and Listeria, other positive cocci (including anaerobic cocci) are sensitive to this product. The antibacterial activity of this product against Staphylococcus aureus is worse than that of cefazolin. 1-2 mg/L of this product can inhibit all Staphylococcus aureus that are sensitive and resistant to penicillin, respectively. It has strong antibacterial activity against Haemophilus influenzae, Escherichia coli, Proteus mirabilis, etc. are sensitive to this product; indole-positive Proteus, Citrobacter and Acinetobacter are poorly sensitive to this product, most Serratia are resistant, Pseudomonas aeruginosa, Campylobacter and Bacteroides fragilis are resistant to this product. The mechanism of action of this product is to inhibit the synthesis of bacterial cell walls.